A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)
Latest Information Update: 23 Jun 2025
At a glance
- Drugs Vafidemstat (Primary)
- Indications Borderline personality disorders
- Focus Therapeutic Use
- Acronyms PORTICO
- Sponsors Oryzon
Most Recent Events
- 17 Jun 2025 Results presented in the Oryzon Media Release.
- 17 Jun 2025 According to an Oryzon media release, final result data from this study was recently published in Psychiatry and Clinical Neurosciences.
- 13 Oct 2024 According to an Oryzon media release, PORTICO's final results were presented at the ECNP New Medication Symposium